Modified Release Hydrocortisone vs Conventional: Which Is Better for Adrenal Insufficiency?

How the Two Formulations Differ at a Pharmacokinetic Level

Conventional immediate-release (IR) hydrocortisone reaches peak serum cortisol within 30-60 minutes and falls to near-baseline within 4-6 hours, forcing a multi-dose schedule. Modified release (MR) tablets use a dual-layer coating that produces an initial small cortisol rise followed by a sustained plateau, lasting up to 7-8 hours from a single morning dose. That difference in the absorption curve has downstream consequences for blood pressure, glucose, and adiposity that have now been quantified in prospective trials.

The natural diurnal cortisol curve peaks between 06:00 and 08:00, then declines steadily through the afternoon and evening. Conventional twice- or thrice-daily dosing creates supra-physiologic spikes in the morning and early afternoon, followed by troughs before each subsequent dose. MR hydrocortisone attenuates those spikes. A pharmacokinetic crossover study published in the European Journal of Endocrinology (N=16, healthy volunteers) showed that Plenadren reduced the cortisol area-under-the-curve coefficient of variation by approximately 30% compared with the same total daily dose of IR hydrocortisone [1]. Lower variability is the point.

Chronocort takes a different approach entirely. Taken at 23:00, it is designed to release most of its cortisol between 04:00 and 08:00, directly targeting the circadian window when cortisol is most needed. A phase III crossover trial published in the Journal of Clinical Endocrinology and Metabolism (N=122) found that Chronocort restored near-normal serum cortisol profiles in patients with congenital adrenal hyperplasia, achieving cortisol peaks of 572 nmol/L vs 319 nmol/L with IR hydrocortisone at 08:00 [2].

Clinical Outcomes: What the Trials Actually Show

The clearest head-to-head evidence for Plenadren vs conventional hydrocortisone in primary adrenal insufficiency comes from the DREAM trial (N=64, 24-week randomized crossover). Patients switched from conventional IR hydrocortisone to Plenadren at the same total daily dose and showed a mean reduction in BMI of 0.9 kg/m2, a reduction in systolic blood pressure of 4.9 mmHg, and a statistically significant improvement in self-reported well-being scores on the AddiQoL questionnaire (P<0.05) [3]. These are clinically meaningful changes given the 24-week duration.

A Swedish registry study covering 1,771 patient-years of follow-up in Addison's disease found that patients on MR hydrocortisone had lower rates of hospital admission for adrenal crisis compared with those on conventional hydrocortisone (2.4 vs 3.8 admissions per 100 patient-years), though the difference was not statistically significant after adjustment for disease duration [4]. The direction of the data supports MR formulations, but the registry design limits causal inference.

Quality of life consistently improves with MR formulations across multiple studies. A systematic review in Clinical Endocrinology (2019) pooling 8 trials and observational studies found standardized mean differences in fatigue scores favoring MR hydrocortisone over conventional by 0.31 SD units [5]. That is a small-to-medium effect by conventional benchmarks. Patients on conventional hydrocortisone frequently describe an energy slump in the early afternoon that corresponds with the mid-day trough. MR hydrocortisone flattens that trough without raising total daily exposure.

Glycemic impact deserves attention. Because conventional IR dosing creates post-absorption cortisol spikes, postprandial glucose excursions are larger with each dose. The European Journal of Endocrinology published continuous glucose monitoring data from 22 patients with secondary adrenal insufficiency showing that peak postprandial glucose was 1.4 mmol/L lower on Plenadren than on conventional twice-daily hydrocortisone [6]. For patients who already have impaired fasting glucose, that difference may prevent progression to type 2 diabetes.

Hydrocortisone vs Prednisone: Choosing the Right Glucocorticoid

Hydrocortisone is the preferred glucocorticoid for adrenal insufficiency in virtually every major guideline. The 2016 Endocrine Society Clinical Practice Guideline states: "We suggest using hydrocortisone (15-25 mg/day in two or three divided doses) or cortisone acetate (20-35 mg/day in two or three divided doses) as the glucocorticoid of choice" [7]. Prednisone and dexamethasone are listed as alternatives, not first-line options.

Why does that preference exist? Three reasons stand out. First, hydrocortisone is bioidentical to endogenous cortisol, which avoids the immunosuppressive and metabolic side effects that accumulate with synthetic analogues at equivalent glucocorticoid potency. Second, the short half-life of hydrocortisone allows dose titration and sick-day adjustments with predictable kinetics. Third, synthetic glucocorticoids like prednisone (potency ratio approximately 4:1 vs hydrocortisone) suppress the hypothalamic-pituitary axis more potently and suppress DHEA production almost completely, eliminating any residual adrenal androgen output.

Prednisone is used in specific clinical situations. Patients with secondary adrenal insufficiency who cannot adhere to multiple daily doses sometimes do better on once-daily prednisone 3-5 mg taken at 07:00. A retrospective analysis of 98 patients with hypopituitarism at a UK tertiary centre found that switching from twice-daily hydrocortisone to once-daily prednisone improved medication adherence self-reporting by 34%, though bone mineral density at the lumbar spine declined by a mean of 1.8% over 18 months on prednisone [8]. That bone loss signal is a real constraint on long-term prednisone use in adrenal insufficiency.

Dexamethasone (0.25-0.5 mg/day) is occasionally used in congenital adrenal hyperplasia to suppress androgen overproduction overnight, but its 36-54 hour biological half-life makes physiologic replacement almost impossible, and it carries a higher Cushing risk per unit of glucocorticoid effect. The Endocrine Society guideline explicitly cautions against dexamethasone for routine adrenal insufficiency replacement [7].

For most patients outside of CAH or documented adherence barriers, hydrocortisone remains the correct choice. The question is which hydrocortisone formulation.

Dosing Practical Guidance for MR vs Conventional Hydrocortisone

Conventional hydrocortisone is typically prescribed as 15-25 mg/day in two or three doses. The most common regimen is 10 mg on waking, 5 mg at 13:00, and (optionally) 5 mg at 17:00-18:00. The evening dose is often omitted because late-day cortisol exposure disrupts sleep quality and interferes with the normal overnight cortisol nadir, which matters for growth hormone secretion and memory consolidation [9].

Plenadren is prescribed as a once-daily dose taken 30 minutes before breakfast. The standard starting dose mirrors the patient's total daily conventional dose (range 20-40 mg/day for the MR formulation). Because the bioavailability of Plenadren is roughly 20% lower than IR hydrocortisone when taken with food, the prescribing information advises taking it fasting [10]. Patients who take it with food may notice inadequate symptom control by mid-morning, which is a common reason for early discontinuation.

Sick-day rules apply identically to both formulations. For fever above 38.5°C, patients should double or triple their total daily dose. For vomiting or inability to take oral medication, parenteral hydrocortisone 100 mg intramuscular injection is required immediately, with emergency services called. The European Society of Endocrinology has produced specific sick-day guidance applicable regardless of formulation [11]. Knowing the formulation matters only for calculating the baseline dose to double. The emergency management is the same.

Switching from conventional to MR hydrocortisone requires no washout period. The patient takes their last conventional dose at bedtime or as normal, then starts Plenadren the following morning at the equivalent total daily dose. Most endocrinologists review cortisol day curves or salivary cortisol profiles at 6-8 weeks after switching to confirm adequate coverage.

DHEA Replacement in Addison's Disease: Evidence and Guidelines

DHEA (dehydroepiandrosterone) is an adrenal androgen that is absent or severely reduced in primary adrenal insufficiency. Conventional and MR glucocorticoid replacement does nothing to restore DHEA. The question of whether to add DHEA supplementation has been debated for two decades, and the evidence remains mixed but usable.

The Endocrine Society 2016 guideline recommends: "We suggest a 6-month trial of DHEA replacement therapy in women with primary adrenal insufficiency who have low libido, depressive symptoms, or impaired well-being despite optimized glucocorticoid and mineralocorticoid replacement" [7]. The target serum DHEA-S concentration is the mid-normal range for age-matched women, typically 1-3 mcmol/L.

What does "optimized glucocorticoid replacement" mean in that sentence? The guideline authors clarified in an accompanying commentary that glucocorticoid dosing should be confirmed at the lowest effective dose before adding DHEA, because over-replacement itself causes fatigue and mood disturbance that can be misattributed to DHEA deficiency [12].

Randomized trial evidence supports a modest benefit. A double-blind crossover RCT published in The New England Journal of Medicine (N=39 women with Addison's disease) found that DHEA 50 mg/day for 4 months improved self-rated health, psychological well-being, and sexual interest compared with placebo (P<0.05 for all three measures), with no significant adverse effects at the 50 mg dose [13]. The effect sizes were not large, but they were consistent across instruments.

A larger Cochrane systematic review (2015, 10 trials, N=967 participants) found that DHEA supplementation in adrenal insufficiency produced a small but statistically significant improvement in health-related quality of life (weighted mean difference 0.17 on the SF-36 mental component, 95% CI 0.05 to 0.29) and improved sexual function in women [14]. Effects on bone density and cardiovascular risk markers were neutral at doses of 25-50 mg/day over 12 months.

The typical starting dose in clinical practice is DHEA 25 mg/day taken in the morning (to mimic natural timing). If serum DHEA-S at 8 weeks remains below the age-matched female reference range, the dose may be increased to 50 mg/day. Monitoring should include serum DHEA-S, testosterone (because DHEA is a testosterone precursor), and clinical assessment for androgenic side effects including acne and hirsutism. Androgenic side effects occur in roughly 15% of women at the 50 mg dose and usually resolve with dose reduction to 25 mg [14].

DHEA replacement is not routinely recommended for men with adrenal insufficiency because the testes maintain testosterone production independently of adrenal androgen output. A male patient with primary adrenal insufficiency who reports fatigue and low libido should first have serum testosterone checked before any DHEA trial is considered.

Monitoring Parameters and Dose Optimization

Optimal glucocorticoid replacement is notoriously difficult to assess biochemically. Serum cortisol measured on conventional hydrocortisone is timed to the dose and reflects absorbed drug rather than physiologic status. A cortisol day curve (samples at 0, 30, 60 to 120 minutes post-dose and at pre-lunch and pre-afternoon-dose timepoints) is the most informative single-day assessment for conventional regimens [15].

For MR hydrocortisone, a modified sampling protocol is recommended: samples at 0, 30, 60, 120, 240, and 360 minutes after the morning Plenadren dose, taken in the fasting state. The European Journal of Endocrinology published reference ranges for Plenadren showing that a peak cortisol of 450-700 nmol/L at 60-120 minutes, with a value above 200 nmol/L at 360 minutes, indicates adequate coverage for most patients [1].

Urinary free cortisol is not recommended for monitoring replacement doses of hydrocortisone because at physiologic replacement doses (15-25 mg/day), UFC typically falls within or below the laboratory reference range. A low or low-normal UFC does not indicate under-replacement. Over-replacement is far more common than under-replacement in clinical practice and carries long-term metabolic and bone consequences comparable to exogenous Cushing syndrome [15].

The 24-hour salivary cortisol profile, collected at home using 4-6 timed specimens, offers a practical alternative to day-curve blood sampling. A 2023 study in Clinical Endocrinology (N=55 patients with Addison's disease) validated salivary cortisol as a reliable surrogate for serum cortisol in patients on both MR and conventional hydrocortisone, with a correlation coefficient of 0.82 [16]. Home-based salivary sampling reduces the clinic burden and provides a more typical daily cortisol exposure pattern than a supervised clinic day curve.

Blood pressure, weight, fasting glucose, and bone mineral density (DXA at baseline and every 3-5 years) round out standard monitoring. Hypertension and central weight gain suggest over-replacement. Postural hypotension and persistent fatigue suggest under-replacement or inadequate fludrocortisone (in primary adrenal insufficiency).

Adrenal Crisis Prevention and Emergency Preparedness

Both MR and conventional hydrocortisone carry the same adrenal crisis risk during physiologic stress. Adrenal crisis is a medical emergency with a reported mortality rate of 0.5 per 100 patient-years in registry data [4]. Physical illness, surgery, gastrointestinal vomiting, and intense exercise are the most common precipitants.

Every patient on any form of glucocorticoid replacement for adrenal insufficiency should carry a medical alert card, wear a medical alert bracelet, and have a self-injectable hydrocortisone kit (100 mg hydrocortisone sodium succinate, IM or SC route) at home and when traveling. The European Society of Endocrinology emergency card specifies the exact sick-day protocol and is available in 27 languages [11].

Patient education reduces crisis rates. A single structured education session reduced adrenal crisis hospitalization rates by 50% over 24 months in a German cohort study of 423 patients with Addison's disease [17]. The education covered sick-day dosing, recognition of prodromal symptoms (nausea, dizziness, increasing fatigue, abdominal pain), and correct self-injection technique.